文献速递淋巴瘤造血干细胞移植与细胞治疗

淋巴瘤患者造血干细胞移植后无事件生存状态对后续生存的影响

Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

虽然达到EFS24和EFS60的患者结局良好,但多数患者生存率仍显著低于年龄、性别和日历期匹配的一般人群。部分特定亚型患者在达到EFS60后生存与一般人群无显著差异,提示可能已治愈。

要点

  • 移植后达到EFS24或EFS60的淋巴瘤患者多数生存仍差于一般人群。
  • DLBCL和FL患者即使达到EFS24或EFS60,标准化死亡比(SMR)仍显著升高。
  • 部分亚型自体移植后达到EFS60者生存与一般人群无显著差异。

核心结论

  • EFS24和EFS60是淋巴瘤患者造血干细胞移植后临床有用的终点。
  • 达到EFS的特定淋巴瘤亚型患者预后与一般人群相当,可能已治愈。

研究设计与样本

  • 基于注册数据的回顾性研究,纳入1981至2018年间因淋巴瘤接受首次自体或异基因造血干细胞移植的患者。
  • 将总生存与年龄、性别和日历期匹配的一般人群进行比较。

主要发现

  • 达到EFS24和EFS60的患者结局良好,但多数生存率仍显著低于一般人群。
  • DLBCL和FL患者达到EFS24或EFS60后SMR仍显著高于一般人群,自体移植后分别为2.5至3.5和2.7至3.7。
  • 霍奇金淋巴瘤患者移植后SMR持续最高。
  • 原发纵隔大B细胞淋巴瘤、血管内大B细胞淋巴瘤和外周T细胞淋巴瘤非特指型患者自体移植后达到EFS60,以及结外NK/T细胞淋巴瘤患者异基因移植后达到EFS60,生存与一般人群无显著差异,SMR分别为1.6、1.2、1.8和1.3。

关键数值与推荐

  • DLBCL和FL自体移植后达到EFS24或EFS60的SMR分别为2.5至3.5和2.7至3.7。
  • 原发纵隔大B细胞淋巴瘤、血管内大B细胞淋巴瘤、外周T细胞淋巴瘤非特指型自体移植后达到EFS60的SMR分别为1.6、1.2、1.8。
  • 结外NK/T细胞淋巴瘤异基因移植后达到EFS60的SMR为1.3。

临床怎么用

  • EFS24和EFS60可用于淋巴瘤移植后生存评估和随访策略制定。
  • 对达到EFS但SMR仍高的亚型(如DLBCL、FL、HL)需持续监测远期死亡风险。
  • 对达到EFS60且SMR与一般人群相当的特定亚型,可考虑按治愈者进行长期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated the impact of event-free survival (EFS) status at 24 months (EFS24) and 60 months (EFS60) after hematopoietic stem cell transplantation (HSCT) using registry data. Patients who underwent their first autologous HSCT (auto-HSCT) or allogeneic HSCT (allo-HSCT) for lymphoma between 1981 and 2018 were included. Overall survival was compared with that of the age-, sex, and calendar period-matched general population. A total of 14 977 patients, including 10 964 and 4013 who underwent auto-HSCT and allo-HSCT, respectively, were analyzed. Although patients who achieved EFS24 and EFS60 had favorable outcomes, most had significantly poorer survival rates than the general population. The standardized mortality ratios (SMRs) of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were significantly higher than that of the general population even after achieving EFS24 or EFS60. The SMRs of those after auto-HSCT were 2.5 to 3.5 and 2.7 to 3.7, respectively. The SMR was consistently highest in Hodgkin lymphoma (HL) patients after HSCT. By contrast, subsequent survival of patients with primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, or peripheral T-cell lymphoma, not otherwise specified, who achieved EFS60 after auto-HSCT, and those with extranodal natural killer/T-cell lymphoma who achieved EFS60 after allo-HSCT did not significantly differ from that of the general population, with SMRs of 1.6, 1.2, 1.8, and 1.3, respectively. Our results suggest that EFS24 and EFS60 were clinically useful end points after HSCT for lymphoma patients. Furthermore, patients with certain lymphoma subtypes who achieved EFS had a comparable prognosis with that of the general population and were potentially cured after HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fujimoto A, Anzai T, Fukuda T, et al. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. Blood Adv. 2021. PMID: 33666656. doi:10.1182/bloodadvances.2020003735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。